Dr. Reynolds is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5301 E Huron River Dr
Ste C139
Ypsilanti, MI 48197Phone+1 734-712-1000Fax+1 734-712-1012
Education & Training
- University of MichiganFellowship, Hematology and Medical Oncology, 1995 - 1998
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1992 - 1994
- University of MinnesotaInternship, Internal Medicine, 1991 - 1992
- Weill Cornell MedicineClass of 1991
Certifications & Licensure
- OR State Medical License 2005 - Present
- MI State Medical License 1995 - 2026
- WA State Medical License 2005 - 2012
- MN State Medical License 1994 - 1996
- NY State Medical License 1993 - 1994
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
- Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2010 Sep 01
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsCobimetinib Plus Vemurafenib in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Rodolfo Gutierrez
JCO Precision Oncology. 2023-09-01 - 2 citationsNivolumab Plus Ipilimumab in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Nitin Rohatgi, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Funda Meric-Bernstam
JCO Precision Oncology. 2023-09-01 - 91 citationsLonger term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) wit...Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein
Blood Cancer Journal. 2020-05-11
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: